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Abstract
Background: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with
metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease,
eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modification and subsequent poor
disease control. We aimed to clarify the effect of EILD on patient survival.
Methods: The medical records of 157 metastatic breast cancer patients treated with eribulin between July 2011
and November 2013 at Cancer Institute Hospital were retrospectively analyzed. EILD was defined as 1) an increase
in alanine aminotransferase or aspartate aminotransferase levels >3 times the upper limit of normal, and/or 2)
initiation of a liver-supporting oral drug therapy such as ursodeoxycholic acid or glycyron. Fatty liver was defined
as a decrease in the liver-to-spleen attenuation ratio to <0.9 on a computed tomography scan.
Results: EILD occurred in 42 patients, including one patient for whom eribulin treatment was discontinued due
to severe EILD. The patients who developed EILD had significantly higher body mass indices (BMIs) than those
who did not develop EILD (24.5 vs. 21.5, respectively; P < 0.0001), with no difference in the dose intensity of
eribulin between the two groups (P = 0.76). Interestingly, the patients with EILD exhibited significantly longer
progression-free survival (PFS) and overall survival (OS) than those without EILD (P = 0.010 and P = 0.032, respectively).
Similarly, among 80 patients without liver metastasis, 19 with EILD exhibited significantly longer PFS and OS than the
others (P = 0.0012 and P = 0.044, respectively), and EILD was an independent prognostic factor of PFS (P = 0.0079) in
multivariate analysis. During eribulin treatment, 18 patients developed fatty liver, 11 of whom developed EILD, with a
median BMI of 26.7.
Conclusions: Although EILD and fatty liver occurred at a relatively high frequency in our study, most of the patients
did not experience severe adverse effects. Surprisingly, the development of EILD was positively associated with patient
survival, especially in patients without liver metastases. EILD may be a clinically useful predictive biomarker of survival,
but further studies are needed to confirm these findings in another cohort of patients.
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Background
Eribulin mesylate is a synthetic analog of halichondrin B,
which is a natural product isolated from the marine sponge
Halichondria okadai. Eribulin is a non-taxane, microtubule
dynamics inhibitor belonging to the halichondrin class of
antineoplastic agents [1].
Eribulin was demonstrated to provide significant sur-
vival benefits in patients with locally advanced and meta-
static breast cancer in a randomized phase III trial that
compared the use of eribulin with the treatment of the
physician’s choice (TPC) [2], and its use was therefore
approved in Japan for breast cancer in July 2011. Cur-
rently, it is widely used to treat locally advanced and
metastatic breast cancer patients in daily practice.
Although eribulin is well tolerated in patients with
heavily pretreated disease [2–5], eribulin-induced liver
dysfunction (EILD) can occur in daily practice and may
result in treatment modification such as dose-delay,
dose-reduction, and treatment discontinuation, leading
to poor disease control. Therefore, we conducted a
retrospective study to clarify the effects of EILD on the
survival of patients with metastatic breast cancer.
Methods
Patients
The medical records of 157 metastatic breast cancer pa-
tients treated with eribulin at the Cancer Institute Hospital
between July 2011 and November 2013 were retrospect-
ively analyzed. This study was approved and the need to
obtain informed consent was waived by the Institutional
Review Board of Cancer Institute Hospital (2015-1048).
Definition of EILD and fatty liver
EILD was defined as follows: 1) an increase in alanine
aminotransferase (ALT) or aspartate aminotransferase
(AST) levels more than three times above the upper
limit of normal, and/or 2) initiation or dose-escalation
of liver-supporting oral drug therapy, such as urso-
deoxycholic acid or glycyron, during eribulin treatment.
If patients already had transaminase levels more than 3
times the upper limit of the normal range at the begin-
ning of eribulin treatment, and showed a further in-
crease apparently due to eribulin, they were diagnosed
with EILD.
Fatty liver was defined as a liver-to-spleen attenuation
ratio of <0.9 on an unenhanced computed tomography
(CT) scan [6]. The mean CT attenuation values of the
liver and spleen were determined in the parenchyma of
the right and left lobes of the liver and of the spleen by
using a 100-mm2 region of interest cursor, avoiding liver
metastases and vessels. CT was performed every 2 or
3 months to evaluate the efficacy of eribulin in most cases.
Statistical analysis
Comparisons between the treatment groups were eval-
uated using the chi-square test, Fisher exact test, or
Mann-Whitney U-test. Progression-free survival (PFS)
and overall survival (OS) curves were generated using
the Kaplan-Meier method and compared using a log-
rank test. Univariate and multivariate Cox proportional
hazards models were used to explore the associations
of specific clinical variables with PFS and OS. For all
tests, differences with P < 0.05 were considered statisti-
cally significant. All analyses were performed using the
JMP 6.0 software package for Windows (SAS Institute
Inc., Cary, NC, USA).
Results
Patient characteristics and EILD status
The patient characteristics are summarized in Table 1.
The median follow-up duration for our cohort was
43.4 weeks (range, 6.0–121.7 weeks). Among the 157
patients treated with eribulin, the median treatment
duration was 16.0 weeks (range, 1.9–112.4), the median
age was 56 years (range, 25–81), the median disease-free
interval was 2.8 years (range, 0–26.5), and the median
body mass index (BMI) was 22.2 (range, 15.8–36.3). All
patients had a performance status (PS) of 2 or less.
Forty-one patients had comorbid diseases including
diabetes (n = 7), hypertension (n = 22), hyperlipidemia
(n = 6), autoimmune disorders (n = 6), cardiovascular
disorders (n = 6), asthma (n = 1), and Parkinson’s disease
(n = 1). However, these diseases had been controlled well
during our observational period. Four patients had a his-
tory of other malignancies (2 uterine cervical cancer, one
renal cancer, and one Hodgkin lymphoma), but they did
not relapse during the follow-up period. Total mastectomy
was performed in 142 patients, 35 patients underwent
breast-conserving surgery, and 6 patients underwent bilat-
eral breast surgery. A total of 93, 95, and 69 % patients, re-
spectively, had been treated previously with anthracycline,
taxane, and capecitabine in the adjuvant or metastatic set-
ting. Among 25 patients with human epidermal growth
factor receptor 2 (HER2)-positive tumors, 13 patients had
received trastuzumab concurrently with eribulin. There-
fore, among the 157 patients treated with eribulin, 144 re-
ceived eribulin monotherapy. Seventy-seven patients had
liver metastases at the start of eribulin treatment.
EILD occurred in 42 (27 %) patients, including ten
patients who required dose-delays or dose-reductions,
and one patient for whom eribulin treatment was dis-
continued due to EILD. Among the patients with EILD,
aminotransferase levels were the highest at a median of
21 days (range, 8–154) after the first eribulin administra-
tion. The median AST and ALT levels at the beginning of
the eribulin treatment were 34 IU/L (range, 17–78) and
23 IU/L (range, 10–65), respectively, and the medians of
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Table 1 Correlation between EILD and clinicopathological variables of the patients treated with eribulin




(n = 157) (n = 42) (n = 115)
Age (years)
Median (range) 56 (25 ~ 81 y) 57 (25–81 y) 52 (38–73 y) 0.37
PS
0 104 34 70 0.05
1 41 7 34
2 12 1 11
Comorbid disease
Yes 41 12 29 0.67
Diabetes 7 4 3
Hypertension 22 9 13
Hyperlipidemia 6 1 5
Others 14 2 12
No 127 31 96
History of other malignancy
Yes 4 0 4 0.57
No 153 42 111
Breast surgery
Yes 142 39 103 0.75
Total mastectomy 101 25 76
Breast-conserving surgery 35 13 22
Bilateral surgery 6 1 5
No 15 3 12
DFI (years)
Median (range) 2.8 (0 ~ 26.5) 3.3 (0–15.6) 2.6 (0–26.5) 0.24
BMI
Median (range) 22.2 (15.8 ~ 36.3) 24.5 (16.8 ~ 36.3) 21.5 (15.8 ~ 35.4) <0.0001
HR (ER/PgR) status
Negative 36 5 31 0.08
Positive 121 37 84
HER2 status
Negative 132 37 95 0.56
Positive 25 5 20
Previous chemotherapy (including adjuvant setting)
Anthracycline
Yes 146 40 106 0.73
No 11 2 9
Taxane
Yes 149 39 110 0.44
No 8 2 5
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the highest AST and ALT levels during eribulin treatment
were 93 IU/L (range, 39–300) and 91 IU/L (range, 37–268),
respectively.
The patients who developed EILD had significantly
higher BMIs than those who did not develop EILD (24.5
vs. 21.5, respectively; P < 0.0001; Table 1), while there was
no difference in the dose intensity of eribulin between
the two groups (0.72 vs. 0.72 mg/m2/week, respectively;
P = 0.76; Table 1). Interestingly, patients with a good PS
exhibited a higher frequency of EILD than those with a
poor PS (P = 0.05, Table 1). The development of EILD was
not associated with other clinical factors such as patient
age, comorbid disease status, history of other malignancy,
primary surgical procedure, disease-free interval (DFI),
hormone-receptor (HR) status, HER2 status, previous
chemotherapy, previous endocrine therapy, type of prior
treatment, and liver metastatic status (Table 1).
Prognostic value of EILD for patient survival
Patients with EILD had significantly longer PFS and OS
than those without EILD (P = 0.010 and P = 0.032, respect-
ively; Fig. 1a and b). Interestingly, this difference appeared
to be specific for patients without liver metastases. Among
the 80 patients without liver metastases, patients with
EILD (n = 19) exhibited significantly longer PFS and OS
compared patients without EILD (n = 61) (P = 0.0012 and
P = 0.044, respectively; Fig. 1c and d). By contrast, EILD
was not significantly associated with PFS or OS in patients
with liver metastases (P = 0.58 and P = 0.28, respectively;
Fig. 1e and f).
In order to clarify the prognostic role of EILD, we con-
ducted multivariate analyses of clinically significant factors
including age, PS, comorbid disease status, DFI, BMI, HR
status, HER2 status, liver metastatic status, and develop-
ment of EILD. In the whole cohort (n = 157), multivariate
analyses identified only PS as an independent prognostic
indicator of better OS (P = 0.0039, Table 2), whereas no
clinical factors were significantly associated with PFS. In
contrast, in the subset of the patients without liver metas-
tases (n = 80), EILD was the only significant independent
predictor of PFS (P = 0.0079, Table 3), and no clinical fac-
tors were significantly associated with OS.
Fatty liver disease during eribulin treatment
During eribulin treatment, 18 (11 %) patients who devel-
oped fatty liver disease had a median BMI of 26.7, which
Table 1 Correlation between EILD and clinicopathological variables of the patients treated with eribulin (Continued)
Capecitabine
Yes 108 25 83 0.13
No 49 17 32
Number of previous endocrine therapy for metastatic disease
0 65 14 51 0.37
1 34 14 20
2 31 7 24
3 18 4 14
4 4 2 2
5 4 1 3
6 1 0 1
Type of prior treatment
Chemotherapy 110 25 85 0.71
Endocrine therapy 42 15 27
No 5 2 3
Liver metastasis
Yes 77 23 54 0.39
No 80 19 61
Concurrent trastuzumab
Yes 13 3 10 0.99
No 144 39 105
Dose intensity of eribulin (mg/m2/week)
Median (range) 0.72 (0.30 ~ 0.91) 0.72 (0.30–0.90) 0.72 (0.32–0.91) 0.76
Abbreviation: EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen
receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
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was significantly higher than that of patients who did
not develop fatty liver disease (26.7 vs. 21.7, respectively;
P < 0.0001). Eleven (61 %) of these 18 patients developed
EILD.
Discussion
In the present study, we found that EILD occurred with
a relatively high frequency, but most patients, except
one, did not experience severe liver damage. In this par-
ticular patient, eribulin treatment was terminated be-
cause the patient’s aminotransferase levels increased to
more than ten times the upper limit of normal and PS
decreased to and remained at 3 even after aminotrans-
ferase levels peaked in the early phase of eribulin treat-
ment. While liver toxicity was uncommon in the global
phase III trial of eribulin vs. TPC, in which 93 % of the
patients were Caucasian [2], a Japanese phase II trial
demonstrated liver toxicity in approximately 30 % of
patients [5]. These studies suggest that ethnicity may in-
fluence eribulin-induced liver toxicity.
To our knowledge, this is the first study to demon-
strate that eribulin induces fatty liver disease, and that
the development of both EILD and fatty liver disease is
significantly associated with higher BMI. These results
indicate that eribulin might precipitate liver damage and
latent fatty liver in patients with obesity. The main mech-
anism of chemotherapy-induced liver injury is thought
to be secondary to the production of reactive oxygen
species (ROS), and steatotic livers are more susceptible
to chemotherapy-induced injury [7]. Presumably, eribulin
might also produce ROS in hepatocytes in a similar
manner, resulting in EILD and fatty liver disease. In
fact, other microtubule-targeted agents such as paclitaxel
and vinorelbine were shown to induce accumulation of
ROS in cancer cell lines, and their anti-tumor effects par-
tially depend on this mechanism [8, 9].
Fig. 1 Progression-free survival (PFS) and overall survival (OS) analyses. a-b: PFS (a) and OS (b) for patients with and without eribulin-induced liver
dysfunction (EILD) among all patients. c-d: PFS (c) and OS (d) for the patients with and without EILD among the patients without liver metastasis.
e-f: PFS (e) and OS (f) for the patients with and without EILD among the patients with liver metastasis
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Paradoxically, we observed a positive correlation be-
tween the development of EILD and patient survival, es-
pecially in patients without liver metastases. Therefore,
EILD may be a clinically useful and easily available
biomarker that can be used to predict the efficacy of eri-
bulin in the early stages of treatment. One possible rea-
son for this finding may be that patients with EILD had
a better nutritional status, and hence, they could survive
Table 2 Cox regression analyses for progression-free survival and overall survival in all patients
Univariate Multivariate
Hazard ratio (95 % CI) P-value Hazard ratio (95 % CI) P-value
Progression-free survival
EILD Yes 1.80 0.013 1.44 0.16
No 1.11–2.88 0.86–2.41
Age ≦56≦56 0.76 0.14 0.76 0.19
>56 0.52–1.10 0.51–1.15
PS 0 1.41 0.089 1.49 0.073
1,2 0.95–2.10 0.96–2.31
Comorbid disease Yes 1.44 0.12 1.51 0.13
No 0.91–2.28 0.88–2.58
DFI ≦2.8≦2.8 1.41 0.069 1.27 0.27
>2.8 0.97–2.06 0.83–1.95
BMI >25 1.64 0.036 1.22 0.47
≦25≦25 1.03–2.59 0.71–2.07
HR (ER/PgR) status Positive 1.49 0.062 1.25 0.37
Negative 0.98–2.28 0.77–2.03
HER2 status Negative 1.60 0.067 1.32 0.30
Positive 0.97–2.65 0.77–2.26
Liver metastasis No 0.95 0.067 0.93 0.72
Yes 0.65–1.38 0.63–1.38
Overall survival
EILD Yes 2.22 0.038 1.75 0.17
No 1.05–4.71 0.78–3.91
Age ≦56≦56 0.81 0.45 0.77 0.37
>56 0.47–1.39 0.43–1.36
PS 0 2.34 0.0021 2.37 0.0039
1,2 1.36–4.03 1.32–4.26
Comorbid disease Yes 0.91 0.77 1.04 0.91
No 0.49–1.70 0.51–2.13
DFI ≦2.8≦2.8 1.78 0.038 1.53 0.18
>2.8 1.03–3.07 0.83–2.85
BMI >25 1.33 0.39 1.13 0.75
≦25≦25 0.69–2.52 0.55–2.31
HR (ER/PgR) status Positive 1.67 0.089 1.15 0.70
Negative 0.93–3.01 0.57–2.29
HER2 status Negative 1.87 0.093 1.42 0.39
Positive 0.90–3.88 0.64–3.16
Liver metastasis No 0.96 0.89 1.00 0.99
Yes 0.56–1.64 0.56–1.79
Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index,
HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
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longer. However, previous studies showed that obesity
was a poor prognostic factor for patients with metastatic
breast cancer [10, 11]. Furthermore, most adjuvant clin-
ical trials showed the same results [12].
Another possible cause of our paradoxical results is
that eribulin-induced ROS production might result in
the eradication of minute metastases consisting mainly
of cancer stem cells (CSCs). The CSC hypothesis has
been widely accepted, and CSCs are considered to play
an important role in the initiation of tumor metastasis
[13–16]. Moreover, ROS have a dual role in cancer pro-
gression. Although ROS are thought to play an important
role in carcinogenesis initiation, malignant transformation,
and cell proliferation, excess ROS production can also
trigger apoptosis of malignant cells [17]. Cellular ROS me-
tabolism is tightly regulated by the redox mechanism, and
Table 3 Cox regression analyses for progression-free survival and overall survival in patients without liver metastasis
Univariate Multivariate
Hazard ratio (95 % CI) P-value Hazard ratio (95 % CI) P-value
Progression-free survival
EILD Yes 3.35 0.0029 3.42 0.0079
No 1.51–7.44 1.38–8.47
Age ≦56≦56 0.64 0.11 0.67 0.20
>56 0.38–1.10 0.36–1.24
PS 0 0.84 0.58 0.68 0.24
1,2 0.46–1.55 0.36–1.30
Comorbid disease Yes 1.59 0.15 1.47 0.32
No 0.85–2.99 0.69–3.15
DFI ≦2.8≦2.8 1.81 0.035 1.79 0.08
>2.8 1.04–3.15 0.93–3.45
BMI >25 1.84 0.073 0.86 0.71
≦25≦25 0.95–3.57 0.38–1.93
HR (ER/PgR) status Positive 1.23 0.46 1.12 0.73
Negative 0.71–2.13 0.58–2.15
HER2 status Negative 1.69 0.14 2.14 0.054
Positive 0.84–3.39 0.99–4.66
Overall survival
EILD Yes 3.93 0.063 3.42 0.13
No 0.93–16.6 0.71–16.44
Age ≦56≦56 0.81 0.59 0.89 0.78
>56 0.38–1.73 0.38–2.09
PS 0 1.73 0.20 1.51 0.36
1,2 0.75–4.02 0.63–3.63
Comorbid disease Yes 1.14 0.76 1.17 0.76
No 0.48–2.71 0.44–3.09
DFI ≦2.8≦2.8 2.52 0.037 1.95 0.19
>2.8 1.06–5.98 0.73–5.25
BMI >25 1.47 0.42 0.87 0.79
≦25≦25 0.59–3.62 0.32–2.40
HR (ER/PgR) status Positive 1.54 0.28 0.97 0.95
Negative 0.71–3.34 0.42–2.28
HER2 status Negative 2.49 0.057 2.20 0.13
Positive 0.97–6.39 0.79–3.09
Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index,
HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
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ROS concentrations are maintained lower especially in
CSCs compared to non-CSCs [18–20]. ROS elevation by
exogenous drugs may be a potential treatment strategy to
selectively kill CSCs [21], and in fact, some chemothera-
peutic drugs have been shown to elicit such an effect on
leukemic stem cells [22–24].
Taken together, these previous evidences described
above support our hypothesis. In fact, we found that,
among the 70 patients without liver metastasis at the be-
ginning of eribulin treatment who were evaluated for
liver metastasis at the final follow-up, the appearance of
new metastatic liver lesions was less frequent in those
who developed EILD than in those who did not (2 of 19
[10.5 %] and 12 of 51 [23.5 %], respectively). This is con-
sistent with our hypothesis that eribulin-induced ROS
production eradicates minute disseminated CSCs in the
liver. However, the difference between these frequencies
was not significant (P = 0.32); therefore, larger studies
are needed to further evaluate this hypothesis.
Conclusions
In summary, although EILD occurred with a relatively
high frequency in eribulin-treated breast cancer patients,
it was generally well tolerated in heavily pretreated pa-
tients in clinical practice. To our knowledge, this is the
first study to show that eribulin may induce fatty liver
disease, and that EILD and fatty liver disease occur more
frequently in obese patients.
We found that EILD was a significant positive prog-
nostic factor for breast cancer patient survival, especially
among patients without liver metastasis. EILD may be a
clinically useful and easily available biomarker that can
be used to predict the efficacy of eribulin in the early
stages of treatment. However, our study was limited by
its small size, retrospective design, and restriction to a
single institute. Therefore, further studies are needed to
confirm our findings in other patient cohorts and to elu-
cidate the mechanism of EILD.
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